3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-[18F] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment.
PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.
Brain and Central Nervous System Tumors
Chronic Myeloproliferative Disorders
Multiple Myeloma and Plasma Cell Neoplasm
Unspecified Adult Solid Tumor, Protocol Specific
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
|Official Title:||Use of [F-18] FLT for Imaging With Positron Emission Tomography (PET)|
- Measurement of the uptake and retention of 3'-deoxy-3'-[18F] fluorothymidine (FLT) in tumors and normal organs [ Time Frame: at time of PET or CT PET Scan ] [ Designated as safety issue: No ]
- Changes in thymidine kinase, thymidylate synthase, and standardized uptake values [ Time Frame: before and after therapy ] [ Designated as safety issue: No ]
- FLT PET response rate [ Time Frame: up to 2 hours during PET scan ] [ Designated as safety issue: No ]
|Study Start Date:||September 2009|
|Estimated Primary Completion Date:||December 2013 (Final data collection date for primary outcome measure)|
The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body.
The tracer compound [F-18] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body. Blood may be withdrawn (through the catheters) up to a total volume of 30 milliliters (or 2 tablespoons) for each scan. A urine sample may be collected at the end of the imaging of the tracer compound to analyze its breakdown products.
Other Name: PET Scan
- Evaluate the use of 3'-deoxy-3'-[18F] fluorothymidine (FLT) positron emission tomography (PET) imaging to measure tumor proliferation and the DNA synthetic pathway (thymidine kinase levels) in patients with cancer.
- Determine the efficacy of FLT PET imaging in detecting lesions and estimating response to treatment.
OUTLINE: Patients undergo up to four 3'-deoxy-3'-[18F] fluorothymidine positron emission tomography imaging procedures.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00935090
|United States, Michigan|
|Barbara Ann Karmanos Cancer Institute||Recruiting|
|Detroit, Michigan, United States, 48201-1379|
|Contact: Clinical Trials Office - Barbara Ann Karmanos Cancer Institute 800-527-6266|
|Sub-Investigator: Shirish Gadgeel, M. D.|
|Sub-Investigator: Ulka Vaishampayan, M.D.|
|Sub-Investigator: Antoinette Wozniak, M.D.|
|Sub-Investigator: Patricia LoRusso, D.O.|
|Sub-Investigator: Elisabeth Heath, M.D.|
|Principal Investigator:||Anthony F. Shields, MD, PhD||Barbara Ann Karmanos Cancer Institute|